A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers
Lynch syndrome tumours share predictable mutations the immune system can target. A vaccine in early trials could be tested to see if it prevents polyps and cancers in carriers.
Nous-209, a frameshift peptide vaccine, has phase 1b data in Lynch carriers showing immunogenicity. Propose a randomised phase 2/3 with adenoma incidence at three years as primary and colorectal cancer incidence as secondary, on a background of aspirin.
- Inherited risk is mostly unidentified · Most people who carry a high-risk cancer gene do not know it until they or a relative gets cancer.
- Prevention we already have is not deployed · Around four in ten cancers are preventable with tools we already own: vaccines, tobacco control, weight, alcohol, sun and infection control.
Pages like this
not linked directly; found by shared links- IdeaA frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval
Shares Cancer interception vaccines for high-risk carriers, First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers, Off-the-shelf cancer vaccines, Neoantigen.
- TermLynch syndrome
Shares First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Inherited risk is mostly unidentified, Endometrial cancer.
- IdeaGet every Lynch syndrome carrier onto the right dose of aspirin
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Inherited risk is mostly unidentified, Prevention we already have is not deployed, Colorectal cancer.
- Key paperCAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Inherited risk is mostly unidentified, Endometrial cancer, Prevention we already have is not deployed.
- TechnologyCancer interception vaccines
Shares First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers, Off-the-shelf cancer vaccines, Colorectal cancer.
- IdeaA therapeutic vaccine to clear cervical precancer without surgery
Shares Cancer interception vaccines for high-risk carriers, Prevention we already have is not deployed.
- IdeaAutomatic germline testing for every cancer type where it changes care
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Inherited risk is mostly unidentified, Colorectal cancer.
- PersonNina Bhardwaj
Shares Off-the-shelf cancer vaccines, Neoantigen.